AbbVie (ABBV)
(Delayed Data from NYSE)
$161.24 USD
+4.93 (3.15%)
Updated May 31, 2024 04:05 PM ET
After-Market: $160.80 -0.44 (-0.27%) 5:12 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Brokerage Reports
AbbVie Inc. [ABBV]
Reports for Purchase
Showing records 61 - 80 ( 378 total )
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for ABBV 71123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 30.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended June 23.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended May 5.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 28.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended April 7.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for ABBV 41123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 31.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for ABBV 4123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for ABBV 32123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 10.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Provider: Zacks Investment Research
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for ABBV 31123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended March 3.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Optimized Entry and Exit Levels for ABBV 3123
Provider: Stock Traders Daily
Analyst: Research Department
Company: AbbVie Inc.
Industry: Large Cap Pharmaceuticals
Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 17.
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D